Scout partnerships, M&A opportunities, and licensing deals across pharma ecosystem with comprehensive deal intelligence
Our Strategic Deal Intelligence service provides comprehensive analysis of M&A opportunities, partnership deals, and licensing agreements across the pharmaceutical ecosystem. We help companies identify high-value targets, assess strategic fit, and optimize deal structures.
Leverage AI-powered deal intelligence to identify non-obvious opportunities, assess competitive landscapes, and make data-driven decisions about strategic transactions.
We continuously scan 5,000+ companies for M&A targets, partnership opportunities, and licensing deals using AI-powered analysis.
Machine learning models assess strategic fit, synergy potential, and complementarity across pipelines and capabilities.
We synthesize deal intelligence into actionable recommendations for deal structure, valuation, and negotiation strategy.
Identify high-value acquisition targets with complementary pipelines and strategic alignment.
Find strategic partnership opportunities with high-fit scoring and synergistic potential.
Identify valuable licensing deals for both in-licensing and out-licensing opportunities.
Assess deal value and structure with comprehensive financial and strategic analysis.
Big Pharma Client • 2024
Identified and facilitated $2.5B acquisition of oncology biotech with complementary pipeline, creating market leadership in 3 therapeutic areas.
Mid-Size Pharma • 2024
Built partnership portfolio of 5 rare disease assets with $800M total deal value, creating leadership in underserved therapeutic areas.